Exemestane

It is a selective aromatase inhibitor (estrogen synthetase), which inhibits the secretion of estrogen. 
Indicated in the treatment of breast cancer in postmenopause. Oral administration once a day for several years.

Since the last update we have not found published data on its excretion in breastmilk.

Its high plasmatic protein binding and very wide volume of distribution make it difficult to pass into breast milk.

Pharmacokinetics show that after 3 elimination half-lives (T½) 87.5% of the drug is eliminated from the body; after 4 T½ it is 94%, after 5 T½, 96.9%, after 6 T½, 98.4% and after 7 T½ it is 99%. From 7 T½ the plasma concentrations of the drug in the body are negligible. In general, a period of at least five half-lives can be considered a safe waiting period before breastfeeding again (Anderson 2016).

According to this data, the interruption of breastfeeding would be for a period of between 5 days (5 T½) to 7 days (7 T½) after the administration of the last dose.

Its administration every 24 hours over many years make it impossible to continue breastfeeding.

See below the information of this related product:

• Maternal Cancer (Unsafe. Moderate/severe adverse effects. Compatible under certain circumstances. Follow-up recommended. Use safer alternative or discontinue breastfeeding from 5 to 7 T ½ . Read Commentary.)